Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/REVIVA PHARMACEUTICALS HOLDINGS, INC./ 8-K

Current Report · Items 2.02, 7.01, 9.01 · 8-K

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPHOTCEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on March 30, 2026, disclosing financial information and operating metrics for its fiscal year ended December 31, 2025 and discussing its business outlook.…

Filed Mar 30, 2026Accepted Mar 30, 2026, 6:11 AM EDTCIK 1742927Accession 0001437749-26-010140
View company →Permanent SEC source ↗
Share

Company context

Current securities

RVPHOTC · EQUITY · Current
Historical securities (4)
RVPHWNASDAQ · WARRANT · Historical · closed Dec 15, 2025TZACNASDAQ · EQUITY · Historical · closed Dec 14, 2020TZACWNASDAQ · WARRANT · Historical · closed Dec 3, 2024TZACWNASDAQ · WARRANT · Historical · closed Dec 14, 2020

Recent company filings

  1. 10-Q filingAug 12, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 12, 2026
  3. 10-Q filingMay 13, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureMay 13, 2026
  5. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsMay 13, 2026

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on March 30, 2026, disclosing financial information and operating metrics for its fiscal year ended December 31, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.